{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T10:56:19Z","timestamp":1777114579539,"version":"3.51.4"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Relapsed\/refractory acute myeloid leukemia (R\/R AML) carries a poor prognosis. We report three patients with R\/R AML, each of whom had relapsed after at least two prior chemotherapy regimens or hematopoietic stem-cell transplantation (HSCT), treated with chidamide, decitabine, venetoclax, and low-dose cytarabine (LDAC) (CHI-DEC-VEN-LDAC). After a single treatment cycle, all three patients achieved complete remission (CR), and two attained minimal residual disease (MRD) negativity. Adverse events were manageable, primarily consisting of cytopenias and infections, with no treatment-related deaths. These results suggest that the therapy is effective and well-tolerated, particularly in patients with R\/R AML who have had extensive prior treatment. The regimen shows promise as a potential bridging or debulking strategy, but further research with larger cohorts and longer follow-up is needed to confirm its long-term efficacy. These cases highlight the potential benefits of chemotherapy-free or low-chemotherapy approaches for R\/R AML treatment.<\/jats:p>","DOI":"10.3389\/fonc.2026.1760614","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T05:19:10Z","timestamp":1771910350000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Chidamide combined with decitabine, venetoclax, and low-dose cytarabine for relapsed\/refractory acute myeloid leukemia: a single-center case series"],"prefix":"10.3389","volume":"16","author":[{"given":"Qing","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3322\/caac.21873","article-title":"Acute myeloid leukemia management and research in 2025","volume":"75","author":"Kantarjian","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"B2","article-title":"Chidamide plus decitabine synergistically induces apoptosis of acute myeloid leukemia cells by upregulating perp","volume":"12","author":"Li","year":"2020","journal-title":"Am J Transl Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s13148-020-00923-4","article-title":"Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (Cdcag) in patients with relapsed\/refractory acute myeloid leukemia: A single-arm, phase 1\/2 study","volume":"12","author":"Wang","year":"2020","journal-title":"Clin Epigenet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.726926","article-title":"A phase ii trial of the double epigenetic priming regimen including chidamide and decitabine for relapsed\/refractory acute myeloid leukemia","volume":"11","author":"Yin","year":"2021","journal-title":"Front Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2042688","article-title":"Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia","volume":"63","author":"Graveno","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.8500","article-title":"Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the european leukemianet recommendations: evaluation of the proposed reporting system","volume":"29","author":"Rollig","year":"2011","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"Dohner","year":"2015","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0b013e3283257a87","article-title":"Second hematopoietic stem cell transplantation in myeloid Malignancies","volume":"16","author":"Arfons","year":"2009","journal-title":"Curr Opin Hematol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.8562","article-title":"International randomized phase iii study of elacytarabine versus investigator choice in patients with relapsed\/refractory acute myeloid leukemia","volume":"32","author":"Roboz","year":"2014","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28974","article-title":"Phase ii, multicenter, randomized trial of cpx-351 (Cytarabine: daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse aml","volume":"121","author":"Cortes","year":"2015","journal-title":"Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e70734","DOI":"10.1002\/cam4.70734","article-title":"Chidamide in combination with dcag with or without venetoclax for relapsed\/refractory acute myeloid leukemia","volume":"14","author":"Liu","year":"2025","journal-title":"Cancer Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.4600","article-title":"Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: A systematic review and meta-analysis","volume":"6","author":"Short","year":"2020","journal-title":"JAMA Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002811","article-title":"Prognostic impact of complete remission with mrd negativity in patients with relapsed or refractory aml","volume":"4","author":"Short","year":"2020","journal-title":"Blood Adv"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-506725","article-title":"Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for aml in first and second complete remission","volume":"122","author":"Walter","year":"2013","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03011","article-title":"Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease","volume":"38","author":"Hourigan","year":"2020","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/cdd.2017.186","article-title":"Bcl-2 family proteins: changing partners in the dance towards death","volume":"25","author":"Kale","year":"2018","journal-title":"Cell Death Differ"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.28091","article-title":"The bcl-2 inhibitor venetoclax inhibits nrf2 antioxidant pathway activation induced by hypomethylating agents in aml","volume":"234","author":"Nguyen","year":"2019","journal-title":"J Cell Physiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.cmet.2019.01.011","article-title":"Systematic dissection of the metabolic-apoptotic interface in aml reveals heme biosynthesis to be a regulator of drug sensitivity","volume":"29","author":"Lin","year":"2019","journal-title":"Cell Metab"},{"key":"B19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30010-X","article-title":"Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: A non-randomised, open-label, phase 1b study","volume":"19","author":"DiNardo","year":"2018","journal-title":"Lancet Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27246","article-title":"Long-term follow-up of viale-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia","volume":"99","author":"Pratz","year":"2024","journal-title":"Am J Hematol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41419-024-06810-7","article-title":"Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia","volume":"15","author":"Nwosu","year":"2024","journal-title":"Cell Death Dis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.canlet.2019.03.046","article-title":"Inhibition of usp9x induces apoptosis in flt3-itd-positive aml cells cooperatively by inhibiting the mutant kinase through aggresomal translocation and inducing oxidative stress","volume":"453","author":"Akiyama","year":"2019","journal-title":"Cancer Lett"},{"key":"B24","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1080\/13543784.2019.1678583","article-title":"Cyclin-dependent kinase (Cdk) 9 and 4\/6 inhibitors in acute myeloid leukemia (Aml): A promising therapeutic approach","volume":"28","author":"Lee","year":"2019","journal-title":"Expert Opin Investig Drugs"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.22284","article-title":"Combined venetoclax and alvocidib in acute myeloid leukemia","volume":"8","author":"Bogenberger","year":"2017","journal-title":"Oncotarget"},{"key":"B26","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/s41419-020-02972-2","article-title":"Preclinical evaluation of a regimen combining chidamide and abt-199 in acute myeloid leukemia","volume":"11","author":"Chen","year":"2020","journal-title":"Cell Death Dis"},{"key":"B27","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.biopha.2017.04.037","article-title":"Chidamide in flt3-itd positive acute myeloid leukemia and the synergistic effect in combination with cytarabine","volume":"90","author":"Li","year":"2017","journal-title":"BioMed Pharmacother"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1760614\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T05:19:11Z","timestamp":1771910351000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1760614\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":27,"alternative-id":["10.3389\/fonc.2026.1760614"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1760614","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"article-number":"1760614"}}